Journal of Behavioral and Brain Science, 2025, 15(3), 47-80
https://www.scirp.org/journal/jbbs
ISSN Online: 2160-5874
ISSN Print: 2160-5866

The Exciting Frontier of Neuroplasticity: Innovations in Brain Health and Recovery

Rishabh Saha

Advanced Surgery Center, Rockville, MD, USA
Email: rishabhsaha5908@gmail.com

How to cite this paper: Saha, R. (2025) The Exciting Frontier of Neuroplasticity: Innovations in Brain Health and Recovery. *Journal of Behavioral and Brain Science*, **15**, 47-80.
https://doi.org/10.4236/jbbs.2025.153003

Received: January 28, 2025
Accepted: March 25, 2025
Published: March 28, 2025

Abstract

Neuroplasticity is the brain's ability to reshape itself by constructing new neural connections throughout life, enabling adaptation to change, learning new information, and recovering from injuries. Neuroplasticity mechanisms underline a range of neurologic and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, stroke, traumatic brain injury, depression, anxiety, and Schizophrenia. In any given year, approximately 20% of adult humans in the United States experience mental illness. The modification of structural and functional activities in the brain, encompassing synaptic plasticity, dendritic remodeling, neurogenesis, and shifts in neurotransmitter systems, significantly influence the progression of these diseases and the manifestation of their symptoms. Clinical trials evaluating therapeutics and biologics are crucial for advancing mental health care, while personalized medicine enhances treatment efficacy for individual patients. These developments hold substantial promise for improving mental health outcomes. Continued research into neuroplasticity is vital for the evolution of therapeutic strategies. This review delves into synaptic, structural, and functional plasticity and its impact on brain injury, neurodegenerative diseases, and psychiatric disorders.

Keywords

Neurological Conditions, Brain Rewiring, Non-Invasive Techniques, Personalized Medicine, Artificial Intelligence, Next-Generation Therapy

1. Introduction: The Brain's Superpower-Neuroplasticity in Action

Neuroplasticity, also known as brain plasticity, is the brain's remarkable ability to reorganize its structure and function by forming new neural connections throughout life. This adaptability enables neurons to adjust their activities in response to intrinsic or extrinsic stimuli, such as learning new skills, recovering from injuries, or adapting to environmental changes. Neuroplasticity encompasses functional changes, like shifting functions from damaged to undamaged brain areas, and structural changes, such as the physical reorganization of neural networks. This dynamic process is essential for learning, memory, and recovery from brain injuries. Additionally, neuroplasticity plays a crucial role in cognitive development, allowing the brain to adapt to new experiences and challenges throughout life. Physical exercise, mental stimulation, and social interactions can enhance neuroplasticity, promoting overall brain health and resilience [1] [2].

Neuroplasticity is crucial for the pathogenesis and treatment of various neurological and psychiatric disorders. It plays a role in the management of neurological disorders like Alzheimer's disease [3], Parkinson's disease [4], stroke [5], and traumatic brain injury (TBI) [6], as well as various psychiatric conditions such as depression, anxiety, and Schizophrenia [7]. Alterations in the brain's structure and function, encompassing synaptic plasticity, dendritic remodeling, neurogenesis, and modifications in neurotransmitter systems, contribute to the progression of diseases and their associated symptoms. Cognitive rehabilitation, physical therapy, pharmacological agents targeting neurotrophic factors [8], and non-invasive brain stimulation techniques [9] are among the strategies aimed at harnessing neuroplasticity to promote recovery, enhance cognitive function, and improve the quality of life for affected individuals [10].

This review aims to deepen the understanding of neuroplasticity by examining the integration of interventions and therapies with advanced neuroimaging techniques, artificial intelligence (AI), and big data analytics to facilitate precision medicine. By exploring these multidisciplinary approaches, the review seeks to elucidate how these technologies can enhance the monitoring and comprehension of neural changes, potentially leading to more effective, personalized therapeutic strategies for neurological conditions.

A mind map illustrating the multifaceted components of brain neuroplasticity is shown in **Figure 1**.

1.1. Types of Neuroplasticity

Neuroplasticity is categorized into structural, functional, and synaptic plasticity (**Figure 1**). It encompasses various processes that enable learning, recovery, and adaptation [11] [12]. Structural plasticity involves physical changes in the brain, such as dendritic branching, where neurons develop new dendrites to create additional synaptic connections between the brain cells [13]-[15]. Another key aspect is myelination, the process of strengthening neural pathways by increasing the insulation of myelin sheath around axons, thereby enhancing the speed and efficiency of neural communication [16]. These structural changes improve learning and cognitive performance and support recovery after brain injuries by allowing the brain to reorganize itself and form new pathways in undamaged regions.

Functional neuroplasticity enables the brain to shift functions from damaged



Figure 1. Multifaceted components of brain plasticity. The central node labeled "brain neuroplasticity" branches into six main categories. Each category further expands into specific topics that contribute to or are affected by brain plasticity. The map uses a color-coding system to differentiate between categories, with connecting lines showing the interrelation of topics across different areas. Prepared via draw.io online software.

or underutilized areas to healthy regions [17]. This is particularly noticeable in brain injuries such as stroke recovery, where intact parts of the brain can take over tasks previously controlled by damaged areas to compensate for lost abilities, restoring essential functions like speech, motor skills, and cognition.

Synaptic plasticity implies the synapses' ability to introduce changes in the strength of neuron connections over time in response to activity levels. This process involves both long-term potentiation (LTP), which strengthens synaptic connections through repeated stimulation to enhance learning and memory retention and long-term depression (LTD), which weakens unnecessary synapses, eliminating redundant connections to improve brain efficiency and adaptability [7] [18]. This balancing act between LTP and LTD helps optimize cognitive processing by fine-tuning neural networks, ensuring that only relevant information is retained for learning and memory.

1.2. Processes of Neuroplasticity

Neuroplasticity is a dynamic and continuous adaptation of neural connections that enables the brain to learn, adjust to new experiences, and recover from injuries. **Figure 1** shows several critical processes that support neuroplasticity, regulating synaptic connections via formation, strengthening, weakening, and elimination.

Synaptogenesis is the creation of new synapses between neurons, enhancing communication and supporting skill development throughout life [19]. At the same time, synaptic pruning refines neural circuits by eliminating weaker or redundant connections, which continue into adulthood, helping the brain focus on and strengthen essential connections. As previously mentioned, LTP and LTD are opposing yet complementary mechanisms of synaptic plasticity that regulate synaptic strength and play a crucial role in the neuroplasticity process [18]. Axonal sprouting allows neurons to extend new axons to reconnect with other neurons after injury, which is vital for restoring lost functions and re-establishing communication pathways.

These interconnected processes allow the brain to reorganize its structure and function, facilitating cognitive development, skill acquisition, adaptation to new experiences, and recovery from neural damage.

1.3. Mechanisms Involved

Neuroplasticity relies on diverse biological mechanisms that regulate neural adaptation, learning, and recovery [20], as shown in **Figure 1**. Neurogenesis involves creating new neurons, especially in the hippocampus brain region, which is essential for memory and learning. This process aids in emotional regulation, cognitive flexibility, and recovery from brain injuries by forming new neural pathways. As mentioned earlier, myelination enhances signal transmission by increasing the insulating sheath around axons, improving neural efficiency, accelerating communication between brain regions, and supporting long-term cognitive function [16]. Gene expression plays a crucial role by regulating the production of proteins necessary for synaptic modifications, neuronal growth, and repair, ensuring that neurons can adapt to environmental changes.

Brain-derived neurotrophic factor (BDNF), along with other neurotrophic factors, is necessary for the growth and survival of neurons [21]. They play a significant role in neurogenesis, synaptic plasticity, and overall brain health. Neurotransmitter systems, including chemicals like glutamate, dopamine, and serotonin, regulate neuroplasticity by influencing synaptic changes and affecting mood and motivation. Another essential mechanism is calcium signaling, which plays a crucial role in adjusting synaptic strength. Calcium ions activate pathways that modify connections based on the type and frequency of neural activity, influencing synaptic plasticity and structural remodeling [22]. Dendritic branching involves growing new dendrites, which enhances a neuron's ability to gather and process information, improving connectivity and playing a crucial role in learning and adapting to new experiences [13] [14].

Together, these interconnected mechanisms drive structural and functional changes in the brain, supporting learning, memory, behavioral adaptation, and injury recovery. By coordinating these processes, the brain continuously evolves in response to experiences, environmental stimuli, and neurodevelopmental changes.

1.4. Factors Influencing Neuroplasticity

Figure 1 presents a range of factors that influence neuroplasticity, shaping the brain's ability to adapt, learn, and heal. Age is a key factor in neuroplasticity, with the brain being most adaptable in childhood due to higher synaptic density. While neuroplasticity declines with age, the brain remains capable of change throughout adulthood, supporting learning and rehabilitation, albeit at a slower rate [10]. Adequate sleep is crucial, as it helps the brain strengthen and reorganize neural connections, supporting learning and memory. Deep sleep facilitates the pruning of unnecessary connections while strengthening important ones [23]. Good nutrition, including foods rich in omega-3s, antioxidants, and vitamins, also support brain health and new neuron growth [24].

Genetics shape an individual's baseline capacity for neural reorganization, influencing cognitive abilities and neurological susceptibility. As we age, this capacity declines, making neuroplasticity-driven recovery and adaptation progressively less efficient.

Environmental stimuli, such as enriched surroundings, sensory experiences, and exposure to new challenges, play a crucial role in strengthening neural connections and fostering cognitive flexibility [25]. Social interactions stimulate brain activity, reinforcing emotional regulation, cognitive development, and overall mental well-being. Physical activity enhances neurogenesis and promotes synaptic plasticity by increasing cerebral blood flow and stimulating the release of neurotrophic factors, such as BDNF, which supports neuron survival and connectivity [21].

Pharmaceutical interventions, including medications and targeted therapies, can modulate neural pathways to enhance or restore plasticity, particularly in neurological and psychiatric conditions. Additionally, emotional and behavioral changes, such as stress management, mindfulness practices, and creative activities, contribute to maintaining a healthy and adaptable brain. Cognitive training, which includes problem-solving, learning new skills, and engaging in mentally stimulating tasks, strengthens neural networks and improves cognitive resilience.

These factors shape neuroplasticity, enabling lifelong learning, injury recovery, and adaptation to new experiences.

1.5. Outcomes of Neuroplasticity

The outcomes of neuroplasticity are profound and wide-ranging [11]. It enhances cognitive abilities, such as learning and memory, by forming and strengthening new neural connections (**Figure 1**). This adaptability is especially valuable after brain injuries, enabling the brain to reorganize and develop new pathways to recover lost functions. One key outcome is enhanced cognitive function, which includes better memory, problem-solving skills, faster information processing, and overall mental agility. This is critical in learning, creativity, and decision-making, allowing individuals to retain and apply knowledge more effectively. Improved motor skills result from strengthened neural connections, leading to better coordination, movement control, and muscle memory, essential for everyday activities and specialized skills such as playing musical instruments or sports.

Neuroplasticity also supports the brain's ability to adapt to new experiences and environments, facilitating skill development and adjustment [12]. In mental health, it aids in better emotional regulation and helps alleviate symptoms of conditions like anxiety and depression. Additionally, neuroplasticity supports motor skill recovery and coordination, which is crucial for rehabilitation after injuries or in managing chronic conditions such as Parkinson's disease. These outcomes highlight the brain's extraordinary capacity to adapt, recover, and thrive, significantly improving cognitive, emotional, behavioral, and physical well-being.

These diverse outcomes highlight the brain's stunning ability to heal, learn, and evolve, emphasizing the importance of engaging in activities that promote neural flexibility throughout life, such as cognitive training, physical exercise, social interactions, and mindfulness practices.

1.6. Applications of Neuroplasticity

Applications of neuroplasticity are extensive and transformative, as shown in **Figure 1**. They play a crucial role in aiding recovery from brain injuries, including strokes, by allowing the brain to rewire and regain lost functions such as movement and speech [11]. Neuroplasticity plays a pivotal role in learning and skill development, enabling individuals to acquire new knowledge, adapt to different learning styles, and improve cognitive performance through targeted training. Techniques such as active recall, spaced repetition, and problem-solving exercises strengthen neural connections, making learning more efficient and long-lasting. It also supports cognitive enhancement, allowing individuals to boost memory, attention, and problem-solving skills through brain-stimulating activities such as puzzles, multilingual learning, and music training. These applications extend beyond traditional education, benefiting professionals acquiring new skills and older adults seeking to maintain cognitive health and delay age-related decline [10].

In healthcare, neuroplasticity is fundamental to therapy and rehabilitation, where physical therapy, cognitive exercises, and neurostimulation help patients recover lost functions after brain injuries, strokes, or neurological disorders. Individuals with neurological disorders, such as Parkinson's disease and Alzheimer's disease, can undergo targeted therapies that encourage the brain to adapt and manage motor and cognitive challenges.

In mental health, neuroplasticity underpins therapies like Cognitive Behavioral Therapy, which helps rewire negative thought patterns and manage conditions such as anxiety and depression [26]. It also plays a crucial role in skill acquisition, cognitive enhancement through brain training, and the development of assistive technologies. These advancements improve the quality of life for individuals with learning disabilities or neurodevelopmental conditions such as attention-deficit/hyperactivity disorder (ADHD) and autism by fostering adaptive behaviors and enhancing functional outcomes through specialized interventions. For children, neuroplasticity aids in addressing developmental disorders, while for older adults, it helps maintain cognitive health and pause the onset of neurodegenerative diseases [27]. Brain neuroplasticity offers transformative benefits across rehabilitation, mental health, learning, and technological innovations, significantly improving overall well-being and quality of life.

2. Interventions to Enhance Plasticity

Several multifaceted approaches are being employed or developed to halt or reverse the progression of neurodegenerative diseases, with a primary focus on enhancing neuroplasticity through a comprehensive strategy. The therapies specifically target essential processes such as neurogenesis, synaptogenesis, synaptic pruning, long-term potentiation, axonal sprouting, dendritic branching, and myelination (**Figure 1**).

Modulating neurological conditions involves diverse approaches to manage symptoms, slow disease progression, and enhance brain function, including pharmacological interventions, lifestyle and behavioral changes, neurostimulation, gene and cell-based therapies, and emerging treatments. A brief overview of estimated proportions is provided in **Figure 2**. As research advances, combining these tailored approaches offers promising outcomes for more effective management of neurological conditions. By focusing on these fundamental mechanisms, the strategy aims to bolster brain resilience, support recovery, and potentially reverse the progression of neurodegenerative conditions. This review will explore key neuroplasticity interventions to enhance brain function and recovery, including medications, gene therapy, lifestyle changes, and non-invasive techniques.

2.1. Pharmacological Interventions

Antidepressants are often prescribed to relieve depression by balancing neurotransmitters like serotonin, norepinephrine, and dopamine in the brain. Beyond depression, they are also used to treat other mood disorders such as anxiety, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD), expanding their range of uses. Specific neuroprotective agents and targeted medications can slow disease progression and enhance synaptic plasticity. Their non-invasive nature, convenience, and ability to complement other treatments, such as neurostimulation and behavioral interventions, make them a valuable component of comprehensive care (**Figure 2**).

Many drugs modulate neurotransmitter systems, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which increase serotonin and norepinephrine levels to promote synaptic plasticity and neuronal excitability. Others, like N-Methyl-D-Aspartate (NMDA)



Figure 2. The diagram illustrates a multidisciplinary approach to neurodegenerative disease treatments, with Pharmacological Interventions (35%) being the most prominent focus, including disease-modifying drugs and neuroprotective agents. Gene Therapy and Precision Medicine (20%) target genetic modulation, biomarkers, and clinical trials to advance personalized care. Lifestyle and Behavioral Interventions (15%) emphasize non-pharmacological strategies like cognitive therapy and rehabilitation. Cell-Based Therapies (10%) explore stem cell and regenerative medicine, while Emerging Therapies plus others (10%) feature innovative approaches like nanomedicine, psychedelics, cannabinoids, mitophagy, autophagy and AI-based omics. Non-Invasive Neurostimulation (10%) employs techniques to modulate neural activity. All % are estimated.

receptor modulators such as ketamine, enhance glutamatergic signaling, increase AMPA receptor trafficking, and reduce excitotoxicity for rapid antidepressant effects [28]. Additionally, neurotrophic factor regulation plays a crucial role, with many antidepressants upregulating BDNF and TrkB signaling to activate pathways like PI3K/Akt and MAPK/ERK, which support neurogenesis and cell survival [21] [29] [30]. Some interventions also target neuroinflammation and oxidative stress, as seen with drugs like minocycline, which mitigate inflammatory responses to preserve synaptic integrity [31]. Emerging epigenetic therapies, including HDAC inhibitors, further influence gene expression related to synaptic plasticity, neurogenesis, and memory formation [32]. These pharmacological strategies enhance neuronal connectivity and functional recovery, making them vital in treating neuropsychiatric and neurodegenerative disorders.

However, these interventions come with limitations, including potential side effects, dependency risks, and systemic toxicity. Many drugs provide only symptomatic relief rather than addressing underlying causes, and long-term use may lead to resistance or tolerance. Individual responses to medications vary due to genetic and metabolic differences, complicating treatment strategies. Furthermore, the high cost and lengthy approval processes for new drugs hinder accessibility and innovation. While pharmacological interventions remain a cornerstone of neuroplasticity-based treatment, their effectiveness is maximized when integrated with other therapeutic approaches while carefully managing risks.

2.1.1. Selective Serotonin Reuptake Inhibitors

Selective serotonin reuptake inhibitors (SSRIs) regulate neurotransmitter activity by stimulating the manifestation of proteins involved in synaptic remodeling, thereby enhancing mood and emotional well-being. Widely prescribed antidepressants in this class, such as fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), paroxetine (Paxil, Pexeva), and citalopram (Celexa), are recognized for their ability to increase neuroplasticity [33]. By inhibiting serotonin reuptake, SSRIs elevate its levels in the brain, initiating neurobiological responses. Notably, they promote neurogenesis, particularly in the dentate gyrus of the hippocampus—a process essential for mood regulation and central to the therapeutic effects of SSRIs. Ongoing research into the neurobiological mechanisms of SSRIs holds promise for the development of more efficient treatments for depression and related mood disorders.

2.1.2. Tricyclic Antidepressants

Tricyclic antidepressants (TCAs), although less frequently prescribed today due to their side effects, are experiencing renewed interest in their potential to enhance neuroplasticity. These antidepressants work by inhibiting serotonin and norepinephrine reuptake, increasing their availability and enhancing synaptic plasticity. Research shows that TCAs, such as imipramine, can elevate BDNF levels, a crucial molecule for neuronal growth, survival, and synaptic plasticity [34]. Animal studies have demonstrated that increased BDNF is associated with improved neuroplasticity in brain regions related to mood and cognitive function [35]. This suggests that TCAs may aid in remodeling disrupted neural circuits in depression, potentially leading to enhanced mood and cognitive outcomes. Further research is needed to explore these effects and their implications for depression treatment fully.

2.1.3. Monoamine Oxidase Inhibitors

Monoamine oxidase inhibitors (MAOIs), such as phenelzine and tranylcypromine, are classic antidepressants that function by inhibiting monoamine oxidase, an enzyme responsible for degrading neurotransmitters like serotonin, dopamine, and norepinephrine. This inhibition leads to enhanced levels of these neurotransmitters in the brain. Historically studied for their effects on neurotransmitter regulation, recent evidence suggests that MAOIs may also foster neuroplasticity [36].

MAOIs have been found to affect the activity of neurotransmitter systems implicated in neuroplasticity, such as the serotonin and dopamine systems [37]. However, compared to SSRIs, research investigating the specific effects of MAOIs on neuroplasticity is relatively scarce, and additional studies are needed to clarify the underlying mechanisms and their potential implications for the treatment of depression and other mood disorders. Despite these limitations, the neuroplasticity-promoting effects of MAOIs represent an intriguing area of research that may offer insights into novel treatment approaches for psychiatric conditions.

2.1.4. Cholinesterase Inhibitors

Cholinesterase inhibitors (ChEIs) play a crucial role in preventing the breakdown of acetylcholine through inhibition of the enzyme acetylcholinesterase and have proven effective in treating neurodegenerative illnesses such as Alzheimer's disease, Parkinson's disease, and Lewy body dementia. Recent evidence also emphasizes their effectiveness in alleviating depressive symptoms. The Food and Drug Administration (FDA) has approved three ChEIs for clinical use: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl). Notably, donepezil has demonstrated antidepressant properties in patients with Alzheimer's disease [38].

2.1.5. N-Methyl-D-Aspartate

N-Methyl-D-Aspartate (NMDA) receptor antagonists play a crucial role in modulating glutamate activity by regulating calcium influx in response to glutamate binding, a process essential for synaptic plasticity and cognitive functions. Excessive activation can lead to excitotoxicity and neuronal damage. Ketamine, a prominent NMDA antagonist, is notable for its rapid antidepressant effects, significantly improving mood within hours by enhancing neuroplasticity and promoting changes in brain circuits related to depression. Thus, ketamine represents a promising option for treatment-resistant depression, highlighting the potential of NMDA receptor modulation in advancing mental health therapies [39].

2.1.6. Neurotrophic Factor Modulators

Modulators target key proteins such as BDNF, nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF), which play crucial roles in neuron survival via intracellular signaling pathways such as MAPK/ERK and PI3K/Akt [21] [29] [35] [40]. Gene expression, dendritic growth, and synaptic remodeling are promoted through these pathways, playing a crucial role in neuroprotection and cognitive function. These proteins help maintain neuronal health and may slow the progression of neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) [41]. However, challenges remain in optimizing delivery methods and ensuring long-term effectiveness.

2.2. Advancing Cell-Based and Gene Therapies through Precision Medicine

Cell-based and gene therapy are cutting-edge advancements in precision medicine, offering promising solutions to brain neuroplasticity (**Figure 2**). Tailoring treatments to each patient's unique genetic makeup, biomarkers, and advanced technologies such as nanomedicine and AI-based OMICS provides a more personalized and targeted way to promote brain healing and recovery. Many of these therapies are non-invasive, reducing patient burden while expanding therapeutic possibilities.

However, significant challenges remain, including high costs that limit accessibility and affordability. Ethical and regulatory complexities, particularly in gene editing and psychedelics, slow down progress, while concerns over unintended genetic effects, immune responses, and long-term safety require continuous monitoring. The variability in patient response further complicates standardization. While these innovative treatments hold immense promises, ongoing research, regulatory support, and cost-reduction strategies are essential to making them widely available and ensuring their safe and effective integration into clinical practice [42].

2.2.1. Cell-Based Therapies

Stem cell transplants, particularly utilizing neural stem cells (NSCs) and mesenchymal stem cells (MSCs), are at the forefront of regenerative medicine for brain disorders [43] [44]. These cells are designed to replace damaged neurons and foster brain repair by secreting essential neurotrophic factors. These factors support neuronal growth, enhance synaptic plasticity, restore neural functions, amplify neuroplasticity, and facilitate functional recovery.

In Parkinson's disease, cell-based therapies focus on replacing lost dopaminergic neurons to restore motor function and improve quality of life [45]. For TBI and stroke, NSCs are injected to rejuvenate cognitive and motor functions, drive neural repair, and establish new neural pathways [46]. Alzheimer's disease treatments involve stem cells that replace lost neurons and mitigate inflammation to enhance cognitive abilities [47]. In ALS, therapies aim to replace damaged motor neurons and offer neuroprotection [41]. Multiple sclerosis is addressed through hematopoietic stem cell therapies that repair neurons and regulate the immune system [48]. Huntington's disease and spinal cord injuries benefit from stem cell treatments that promote neuron regeneration and functional recovery [49]. Additionally, epilepsy treatments focus on replacing impaired inhibitory neurons to reduce seizure activity, while neurodevelopmental disorders such as autism are being targeted with stem cells to support brain development and neurological function [50]-[52].

2.2.2. Gene Therapies

Gene therapy is revolutionizing the treatment of neurological disorders by directly targeting their genetic causes and enhancing the brain's repair mechanisms. Cutting-edge gene editing technologies like CRISPR-Cas9 [53] and advanced viral vector systems enable precise interventions to correct genetic abnormalities and boost neuroplasticity. In ALS, gene therapies aim to deliver protective genes like SOD1 to shield motor neurons from degeneration [50]. For Alzheimer's disease, research focuses on enhancing neuroprotective factors such as BDNF to combat cognitive decline [21]. Spinal muscular atrophy (SMA) is being addressed with innovative treatments like Zolgensma, which supplies a functional SMN1 gene to support motor neuron survival [54]. Additionally, gene therapies are showing promise in Parkinson's disease by restoring dopamine production [55] and in Batten disease by correcting the defective CLN3 gene [56]. These groundbreaking approaches are transforming the treatment landscape and advocating renewed hope to patients and their families, signaling a new era in the fight against neurological diseases.

2.2.3. Precision Medicine Approach

Precision medicine is reforming neurological disorder treatments by customizing therapies to individual genetic profiles, biomarkers, and personal characteristics. This approach enables patient-specific treatments through genetic sequencing and biomarker analysis, identifying those most benefit from targeted interventions. Personalized gene editing can address unique genetic mutations in neurodegenerative diseases, optimizing patient outcomes.

Clinical trials use genetic data to refine how drugs interact with a person's unique genetic makeup, ensuring that neuroplasticity-enhancing therapies are more effective and have fewer side effects. Resources like the NINDS Neurogenetics Repository Project provide researchers with DNA samples and clinical information from patients with neurological disorders. By analyzing these genetic insights, scientists can determine which treatments work best for specific individuals, advancing precision medicine. This approach helps tailor therapies to each patient, optimizing drug efficacy while minimizing adverse effects [57]. This strategy promises to transform neurological care by delivering more precise and effective treatments.

2.2.4. Targeting Cellular Processes and Emerging Therapies

Nanoparticles are modernizing the treatment of neurodegenerative diseases by precisely delivering encapsulated small molecules, proteins, and DNA. These particles can cross the blood-brain barrier, allowing targeted central nervous system (CNS) treatments and early diagnosis. In Parkinson's disease, liposomes and dendrimers deliver neurotrophic factors that protect neurons and alleviate motor symptoms [58]. Alzheimer's research is advancing with nano-encapsulated antibodies to clear amyloid plaques, potentially slowing cognitive decline [59]. For multiple sclerosis, nanoparticles are being developed to deliver anti-inflammatory drugs directly to the CNS, reducing disease activity with fewer side effects. Additionally, nanoparticle-based therapies are exploring ways to promote nerve regeneration and repair in spinal cord injuries, offering hope for functional recovery [60].

Nanoparticles play a vital role in controlled drug release, enabling sustained therapeutic levels over extended periods and minimizing the need for frequent dosing. They also enhance diagnosis through innovative techniques, such as using gold nanoparticles to detect Alzheimer's biomarkers and quantum dots to visualize Parkinson's biomarkers [61]. These advancements contribute to more precise treatments and facilitate more accurate disease detection, representing significant progress in precision medicine.

Researchers are developing therapies that enhance autophagy and mitophagy to protect neurons and slow neurodegenerative disease progression [62]. The primary focus is to target key regulatory pathways such as mTOR (mechanistic target of rapamycin) and AMPK (AMP-activated protein kinase). For example, mTOR inhibitors like rapamycin and AMPK activators like metformin have shown potential in preclinical studies for boosting cellular cleanup and mitigating neurodegeneration in Parkinson's and Alzheimer's diseases [63] [64]. Additionally, compounds like spermidine and therapies targeting mitophagy-related proteins, such as PINK1 (PTEN-induced putative kinase 1) and Parkin, aim to improve neuronal survival and function by enhancing the removal of damaged components and supporting mitochondrial quality control [65]. These innovative approaches offer promising new strategies for treating and managing neurodegenerative conditions.

Psychedelics like psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), and lysergic acid diethylamide (LSD) are being explored for their potential in treating neurodegenerative diseases by enhancing neuroplasticity and modulating neurotransmitter systems, particularly serotonin. Clinical trials are investigating their long-term benefits, with early results suggesting potential improvements in cognitive function and overall quality of life for patients with advanced neurodegeneration [66].

Cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), are gaining attention for their neuroprotective and anti-inflammatory properties. These compounds intermingle with the endocannabinoid system to modulate immune responses, reduce neuroinflammation, and alleviate oxidative stress, factors critical in neurodegenerative diseases like ALS and Parkinson's [67].

AI-driven omics—encompassing genomics, proteomics, and metabolomics—are transforming the understanding and treatment of neurodegenerative diseases by providing deep insights into patients' genetic, protein, and metabolic profiles. AI analyzes large-scale genetic data to identify mutations and genetic markers linked to neurodegeneration, guiding the development of targeted gene therapies and personalized medicine [68].

2.3. Lifestyle and Behavioral Interventions

In recent years, there has been growing interest in leveraging the principles of neuroplasticity within cognitive therapy, rehabilitation, physical activity, and dietary modifications to enhance outcomes for individuals recovering from brain injuries, neurological conditions, or other impairments (**Figure 2**). It offers a holistic, non-invasive, cost-effective approach to enhancing neuroplasticity and brain health. These interventions are widely accessible and serve as both preventive and rehabilitative strategies, helping individuals recover from brain injuries or neurodegenerative diseases. Additionally, they complement other treatments like neurostimulation, pharmacological therapies, and emerging medical approaches, creating a well-rounded therapeutic framework for neurological care.

However, their effectiveness depends on long-term adherence, which can be challenging for individuals with cognitive impairments or mobility limitations. Unlike pharmacological treatments, lifestyle changes require consistent effort and may take longer to produce noticeable benefits. Effectiveness also varies based on genetics, environmental factors, and access to professional support. While these interventions play a crucial role in brain health, they are often insufficient as standalone treatments for severe neurological conditions, necessitating integration with other medical approaches for optimal outcomes.

2.3.1. Integrating Cognitive, Behavioral, and Physical Therapies for Comprehensive Neurological Rehabilitation

These approaches comprehensively address the mental, emotional, and physical challenges faced by people with neurological conditions. Combining methods such as retraining the brain to think differently, changing behaviors, and using targeted rehabilitation exercises helps the brain heal and function better, ultimately improving the patient's quality of life. Cognitive therapy focuses on altering negative thoughts, beliefs, and attitudes, particularly in cases of depression, anxiety, or brain injuries. Techniques like cognitive restructuring help individuals replace negative thoughts with positive ones, while attention and memory training enhance focus and recall. Problem-solving skills teach people to break down complex tasks into manageable steps. Cognitive Behavioral Therapy [26] integrates these methods to address negative thoughts and behaviors tailored for those with brain conditions. Community support is crucial, as well as providing additional resources, encouragement, and social connections that reinforce therapy and foster a supportive environment for recovery.

Behavioral therapy is vital for overcoming harmful habits and behaviors that impact recovery and quality of life, especially for those with disabilities or brain injuries [69]. It helps rebuild lives and promote independence through methods like behavior modification, which uses rewards to reinforce positive behaviors, and exposure therapy, which assists people in facing and overcoming fears related to anxiety, PTSD, or trauma from conditions like strokes. Behavioral activation encourages patients to engage in enjoyable activities to improve mood and rehabilitation outcomes, while habit reversal addresses unhelpful patterns, such as favoring one side of the body after a stroke, by replacing them with more functional behaviors. These therapies provide practical solutions and hope, empowering patients to regain control, with community support playing a vital role in their recovery.

Rehabilitation therapy is focused on restoring physical and cognitive functions lost due to injury, illness, or developmental disorders [70]. It encompasses targeted therapies such as physical therapy for improving movement and coordination, occupational therapy for daily tasks, and speech and language therapy for communication skills. Neuropsychological rehabilitation addresses cognitive functions like memory and problem-solving through personalized plans designed to retrain or compensate for impaired abilities. Successful rehabilitation therapy requires a patient-centered approach, focusing on individual needs and consistent practice to build new neural connections. Advances in telehealth technology are increasingly facilitating remote delivery of rehabilitation services, which is particularly beneficial when in-person therapy is not feasible. Home-based rehabilitation programs and telerehabilitation platforms allow individuals to receive ongoing support from therapists while participating in therapy activities at home [71]. Family, caregivers, and community resources are vital to patient engagement and recovery. Rehabilitation therapy is effective for stroke rehabilitation, TBI recovery, mental health management, and neurodegenerative disease symptom management, providing a comprehensive path to improved functionality and quality of life [72].

2.3.2. Optimizing Neurological Health: The Power of Diet, Exercise, and Lifestyle

Lifestyle interventions, particularly dietary modifications, are crucial for managing neurological conditions and enhancing brain health [23] [24]. A diet rich in specific nutrients can have a profound impact. Incorporating foods such as fatty fish like salmon, mackerel, and sardines, which are high in Omega-3 fatty acids, supports cognitive function and may help protect against neurodegeneration. Berries, including blueberries, strawberries, and blackberries, are rich in antioxidants that reduce inflammation and boost memory. Nuts and seeds, such as walnuts, almonds, and flaxseeds, provide healthy fats and essential nutrients for brain health. Leafy greens like spinach, kale, and collard greens, packed with vitamins and minerals, contribute to cognitive function. Whole grains such as oats, quinoa, and brown rice offer steady energy and support overall brain health, while legumes like beans, lentils, and chickpeas supply fiber and vital nutrients. Cutting back on processed foods, sugary snacks, and unhealthy fats reduces inflammation and prevents symptom progression.

Alongside dietary changes, integrating regular physical activity, such as walking or strength training, enhances brain health by improving blood flow and cognitive function. Adequate sleep is critical for brain recovery and memory consolidation, while effective stress management techniques, including mindfulness and relaxation exercises, help reduce inflammation and prevent cognitive decline. Combining a nutrient-rich diet with regular exercise, proper sleep, and stress management can significantly improve neurological health and overall quality of life [23].

2.4. Non-Invasive Neurostimulation

Brain stimulation methods have been gaining traction due to their ability to alter brain function and foster neuroplastic changes (**Figure 2**). These techniques are increasingly being explored for their potential applications in manipulating neural activity [73]. Non-invasive and minimally invasive neurostimulation provides a safe and effective method to enhance neuroplasticity without the risks associated with surgical interventions. These techniques are widely applied in treating neurological and psychiatric conditions, supporting stroke recovery, brain injuries, and cognitive enhancement. A key advantage of these approaches is their seamless integration with other therapies, such as cognitive training and pharmacological treatments, to improve patient outcomes. Additionally, advanced imaging tools enable real-time monitoring, allowing for personalized treatment adjustments and optimization of protocols.

Despite its advantages, neurostimulation's effectiveness varies among individuals, and some benefits may be temporary, requiring repeated sessions to maintain results [74]. The side effects, including headaches, mild discomfort, and potential unintended neural changes, are of great concern. Accessibility is another limitation, as the high cost of specialized equipment and treatment sessions restricts widespread use. Neurostimulation holds immense potential for neurological care, and further research is necessary to enhance long-term efficacy, affordability, and broader clinical implementation.

2.4.1. Transcranial Magnetic Stimulation

Transcranial magnetic stimulation (TMS) involves the non-invasive delivery of brief magnetic pulses to specific brain regions, generating electrical currents that can depolarize neurons and modulate neural activity. In clinical settings, repetitive TMS (rTMS) is FDA-approved for treating depression, particularly in individuals who haven't responded to traditional antidepressant medications. TMS is being investigated for its potential to treat neuropsychiatric conditions like anxiety disorders, Schizophrenia, and chronic pain [75]. It also serves as a valuable research tool for studying brain function, mapping cortical regions, and exploring the effects of brain stimulation on cognitive processes.

Beyond its research applications, TMS has demonstrated its ability to induce neuroplastic changes in the brain, comprising alterations in cortical excitability, synaptic strength, and connectivity. TMS can facilitate adaptive changes in neural circuits by targeting specific brain regions implicated in various functions. These changes, in turn, lead to improvements in symptoms and cognitive performance, offering promise for enhancing treatment outcomes across a spectrum of neurological and psychiatric conditions [75].

2.4.2. Transcranial Direct Current Stimulation

Transcranial direct current stimulation (tDCS) provides a non-invasive approach to modulating brain activity by utilizing a low-intensity electrical current to the scalp through electrodes. This method adjusts the resting membrane potential of neurons, influencing their firing patterns and overall activity levels. With its affordability, portability, and ease of administration, tDCS has garnered attention across a broad spectrum of applications, including cognitive enhancement, motor rehabilitation, pain management, and neuropsychiatric treatment [76]. Researchers are actively exploring its potential as an adjunctive therapy for conditions such as depression, chronic pain, stroke, Parkinson's, and Alzheimer's diseases, making it a promising tool for clinical and research settings.

Studies have revealed that tDCS induces changes in cortical excitability and synaptic plasticity, resulting in lasting alterations in brain function. Targeting specific brain regions, tDCS promotes neural reorganization, facilitating functional recovery in individuals with neurological or psychiatric conditions. Often used with behavioral interventions, tDCS aims to maximize its therapeutic effects, fostering enduring improvements in brain function and behavior. These findings highlight the potential of tDCS as a versatile and effective tool for modulating brain activity and promoting neuroplasticity, with implications for enhancing treatment outcomes across neurological and psychiatric disorders [77].

2.4.3. Electromyography

Electromyography (EMG) sensors serve as vital tools in clinical and research settings, offering insights into skeletal muscles' electrical activity and playing a significant role in neuroplasticity. By monitoring muscle activity, EMG provides insights into how neural pathways adapt and change in response to injury, rehabilitation, or skill acquisition. These sensors, typically comprising small electrodes, detect and record the signals generated by muscle contractions. In clinical applications, EMG is instrumental in diagnosing neuromuscular disorders, assessing nerve function, and evaluating muscle health. By capturing the intricate patterns of muscle activity, EMG aids in understanding the underlying mechanisms of various conditions and guiding treatment strategies and rehabilitation plans. Recent developments in EMG sensor technology have led to the creation of wearable devices that offer real-time monitoring of muscle activity in diverse settings. Combining EMG with tDCS and TMS offers a promising approach to modulate brain activity and enhance motor learning and rehabilitation outcomes by targeting specific neural pathways associated with muscle activation and control [78].

2.4.4. Electroencephalography

Electroencephalography (EEG) is a powerful tool for elucidating the intricate processes of neuroplasticity [79]. By monitoring the brain's electrical activity through electrodes placed on the scalp, clinicians can observe shifts in neural connectivity, synchronization, and activation patterns associated with neuroplastic changes. For individuals recovering from stroke, TBI, or neurodegenerative diseases, EEG can be used to monitor changes in brain activity indicative of neural recovery and adaptation. Clinicians leverage this information to tailor rehabilitation interventions to promote neuroplasticity and maximize functional outcomes.

Combining EEG with tDCS and TMS offers a comprehensive approach to studying and modulating brain activity [78]. EEG provides real-time monitoring of neural activity, allowing researchers to observe how tDCS and TMS influence brain oscillations, connectivity, and cortical excitability. This integrated approach enhances our understanding of neuroplasticity mechanisms and aids in optimizing stimulation protocols for therapeutic interventions targeting neurological and psychiatric conditions. Additionally, EEG-TMS and EEG-tDCS techniques offer promising avenues for personalized medicine, allowing clinicians to tailor stimulation. The parameters are based on individual brain activity patterns, ultimately leading to more effective treatments.

Overall, all these non-invasive brain stimulation techniques can modulate neuroplasticity and promote adaptive changes in the brain. Continued research into their mechanisms of action, optimal parameters, and clinical applications will further advance our understanding of how these methods can be utilized to augment brain function and improve outcomes for individuals with various neurological and psychiatric conditions.

2.4.5. Deep Brain Stimulation

Deep brain stimulation (DBS) is a minimally invasive technology that involves surgically implanting electrodes in specific brain regions to modulate neuronal activity through electrical impulses [80]. DBS is utilized in the treatment of movement disorders such as Parkinson's disease. It can dramatically reduce motor symptoms like tremors and stiffness, significantly improving patients' quality of life. The procedure allows for better control of abnormal brain activity that medications may not fully address. Additionally, ongoing research is exploring DBS for psychiatric conditions like depression and OCD, as well as cognitive disorders, to offer new treatment options for these challenging conditions.

2.4.6. Functional Magnetic Resonance Imaging

Functional magnetic resonance imaging (fMRI) is a brain imaging technique that measures neural activity by tracking changes in blood flow. When a specific brain region becomes more active, it demands more oxygen, leading to increased blood flow, which fMRI detects in real-time. This provides highly detailed images of brain activity and functioning. By combining fMRI with neurostimulation methods such as TMS or tDCS, clinicians can more precisely target regions of the brain that show abnormal patterns of activity. This advanced approach allows personalized treatments tailored to an individual's brain activity, enhancing the effectiveness of interventions for neurological and psychiatric conditions by directly modulating the most affected areas [81]. Additionally, it can be used to monitor the brain's response to therapy in real-time, adjusting treatments as needed to optimize patient outcomes.

2.4.7. Diffusion Tensor Imaging

Diffusion tensor imaging (DTI) is an advanced type of MRI that maps explicitly the movement of water molecules in brain tissue. It is beneficial for visualizing white matter tracts, the nerve fibers that unite different brain regions [82]. Unlike standard MRI, which captures the brain's structure, DTI focuses on how water moves along these pathways, providing insight into the brain's connectivity. By tracking water diffusion, DTI can detect damage or abnormalities in white matter, which is crucial in conditions like TBI, multiple sclerosis, and neurodegenerative diseases. It helps understand the structural integrity of neural pathways, making it a valuable tool for diagnosing brain disorders and monitoring the effectiveness of treatments to restore or preserve brain function.

2.4.8. Neurofeedback

Neurofeedback involves training individuals to alter their brain activity through real-time EEG monitoring and feedback. This technique allows individuals to see their brainwave patterns and learn to influence them consciously. It improves mental health, enhances cognitive functions, and treats neurological conditions such as ADHD, anxiety, and epilepsy [83]. By promoting self-regulation of brain states, neurofeedback can modulate lasting alterations in brain function and behavior, providing a non-invasive approach to mental health and cognitive enhancement.

2.4.9. Brain-Computer Interfaces

Brain-computer interfaces (BCIs) permit direct interaction between the brain and external devices. BCIs translate neural signals into commands, enabling control of computers, prosthetics, and other electronic devices. This technology offers new possibilities for individuals with disabilities, such as those with paralysis or amputations, by providing them with greater independence and control over their environment. BCIs also potentially enhance human-computer interaction, enabling more intuitive and efficient ways to interact with technology [84].

Both neurofeedback and BCIs represent significant advancements in harnessing brain activity to improve health, augment abilities, and enhance quality of life. These technologies provide therapeutic benefits and open new avenues for research and innovation in neuroscience, rehabilitation, and human augmentation. As these fields continue to develop, they promise to revolutionize how we understand and interact with our brains and the world around us.

2.4.10. Non-Invasive Vagus Nerve Stimulation

Non-invasive vagus nerve stimulation (nVNS) is a therapeutic technique that stimulates the vagus nerve through the skin without surgical implantation. The vagus nerve is a major nerve that links the brain to various organs, including the heart and gut and regulates numerous physiological processes [85].

In nVNS, a small, hand-held device delivers electrical pulses to the skin over the area where the vagus nerve is close to the surface, usually on the neck or ear. These pulses modulate brain activity by influencing the vagus nerve, which can help in treating conditions like epilepsy, depression, and migraines. By stimulating the vagus nerve, nVNS aims to balance neurotransmitter levels and improve brain function, offering a non-invasive alternative to invasive nerve stimulation methods. This technique provides a promising alternative for patients who may not respond well to conventional treatments or seek a less invasive approach.

2.4.11. Low-Intensity Focused Ultrasound

Low-intensity focused ultrasound (LIFU) is a therapeutic technique that uses ultrasound waves to target specific brain regions precisely [86]. LIFU operates at lower intensities than other ultrasound methods, modulating brain activity without causing damage. In LIFU, focused ultrasound waves are directed at a precise point in the brain, where they can alter neural activity or stimulate specific brain regions. This technique allows for targeted neuromodulation, which can be beneficial in treating neurological and psychiatric conditions such as depression, chronic pain, and movement disorders. The non-invasive nature of LIFU and its ability to target brain regions with high precision make it a promising tool in research and clinical applications [87].

3. Challenges in Neuroplasticity Research and Practice

Neuroplasticity offers promise, but its clinical application faces significant challenges. **Figure 3** highlights critical challenges such as tracking brain changes, accounting for patient variability, ensuring long-term effectiveness, addressing resource limitations, ethical concerns, and the need for collaboration to achieve successful implementation.



Figure 3. The diagram delineates eight critical challenges. An icon symbolizes each challenge, all interconnected to the central theme, emphasizing the multifaceted nature of neuroplasticity research. Prepared via draw.io online software.

3.1. Health Education and Brain Adaptability

Health education can enhance brain functioning by promoting growth and adaptability through acquiring new habits and knowledge (**Figure 3**). By consistently engaging in learning, the brain can strengthen its neural pathways, fostering improved cognitive abilities [23]. However, several challenges can hinder this process. Cognitive overload may occur when excessive information overwhelms the brain, reducing its ability to process and retain knowledge. Resistance to breaking old habits can significantly impair the brain's capacity to adapt to new information. Furthermore, a lack of motivation may prevent individuals from effectively applying what they've learned, limiting the benefits of health education. Complex brain disorders, such as neurodegenerative diseases, further complicate these processes by making neuroplasticity more difficult to achieve. Therefore, balancing the delivery of information, addressing motivational barriers, and providing targeted interventions for brain disorders are crucial to optimizing the positive effects of health education on neuroplasticity.

3.2. Ethical and Privacy Concerns

The collection of extensive personal data in neuroplasticity research presents significant ethical and privacy concerns, making it crucial to balance data acquisition with the protection of patient confidentiality (**Figure 3**). Maintaining trust between patients, researchers, and healthcare providers is essential for the success of such studies. Future efforts must prioritize implementing comprehensive data security measures while establishing clear ethical guidelines and regulations. These should include advanced encryption of protocols, stringent access controls, and robust anonymization techniques to safeguard patient privacy without compromising research quality. Furthermore, ethical oversight must adapt to address evolving concerns in data handling and patient consent. By emphasizing these security measures and ethical considerations, the field can maintain high patient confidentiality, trust, and integrity standards in neuroplasticity research and practice, promoting scientific progress and fostering public confidence [88].

3.3. Individual Variability and Long-Term Success

Understanding how the brain adapts and heals is inherently complex, primarily due to individual characteristics and physiological differences (**Figure 3**). Variables such as age, genetics, lifestyle factors, and the severity of brain damage significantly impact how well a person responds to specific treatments [24] [89]. These variations make developing one-size-fits-all therapies particularly difficult, as different patients may experience vastly different outcomes. Personalized medicine, which incorporates detailed genetic, epigenetic, and biomarker data, enables the customization of treatments that align with each person's unique biological profile. This tailored approach increases the likelihood of effective therapeutic outcomes by addressing the patient's specific needs, genetic predispositions, and overall health circumstances. Such precision optimizes treatment effectiveness and reduces potential side effects, making personalized medicine a cornerstone in advancing brain healing and neuroplasticity research.

However, sustaining these benefits over the long term presents additional challenges. Treatments that initially yield positive results might not always maintain efficacy due to the dynamic nature of brain adaptation and evolving conditions over time. The brain's needs and responses are not static, so therapies must be continually reassessed to remain effective. This emphasizes the significance of ongoing monitoring and adjustments to treatment protocols. Personalized strategies, which already enhance initial success rates, become even more critical in ensuring long-term improvements in brain health. By adapting treatments to the brain's changing needs, personalized approaches can help maintain their efficacy and support continuous recovery, ultimately leading to more durable outcomes in neuroplasticity and brain health interventions.

3.4. Integration of Multimodal Data

Integrating data from various sources, such as EMG and EEG, into a cohesive framework for analysis presents a substantial challenge due to differing data formats and the significant volume of information involved (**Figure 3**). This complexity can overwhelm researchers and clinicians, making extracting meaningful insights into neuroplastic changes difficult. Future initiatives should prioritize the development of sophisticated data integration and analysis platforms capable of effectively managing multimodal data. These platforms must be designed to synthesize information from diverse sources, providing in-depth insights into neuroplasticity. By leveraging such tools, researchers and clinicians will enhance their understanding of neural processes and develop more targeted interventions for neurorehabilitation. This approach improves data usability and fosters collaboration among researchers and healthcare professionals. Eventually, it will lead to better patient outcomes for those affected by brain-related conditions, driving innovation in treatment strategies and advancing the field of neurorehabilitation.

3.5. Technological Limitations

Wearable and sensor-based technologies face several key challenges that can hinder their effectiveness in healthcare (**Figure 3**). Limitations in accuracy and sensitivity often lead to inconsistent data, which can compromise clinical decision-making. User-friendliness is another critical issue; if devices are not intuitive or easy to navigate, patients may disengage, reducing compliance and data collection. Additionally, the sheer volume of data generated can overwhelm patients and healthcare providers, making it difficult to extract actionable insights without robust analytical tools.

Integrating machine learning (ML) and AI can help address these challenges. For instance, ML algorithms can filter out noise and identify significant trends in the data, making it simpler for healthcare providers to make informed decisions. AI can also enhance user interfaces, creating more personalized and engaging experiences and encouraging patients to use the devices consistently. However, there are additional challenges to consider: ensuring the accuracy of these algorithms, protecting patient privacy and security, and achieving seamless integration with existing healthcare systems. Furthermore, there may be a learning curve for healthcare professionals to adapt to these new technologies, and ensuring equitable access for all patients is critical. By tackling these issues, ML and AI can significantly improve the reliability and usability of wearable technologies in neurorehabilitation and other medical fields.

3.6. Accessibility and Cost

Advanced neurorehabilitation technologies and personalized therapies pose significant challenges due to their high costs, limiting accessibility, particularly in low-resource settings (**Figure 3**). This financial barrier restricts many patients from accessing potentially life-changing treatments. Future efforts should focus on reducing costs through technological innovation and developing scalable, widely distributed solutions. This may involve leveraging manufacturing processes, materials, and design advancements to produce affordable yet effective devices and therapies.

In addition to high costs, challenges include the need for expert training for healthcare providers to use these advanced technologies, which can further limit their implementation. There may also be regulatory hurdles that slow down the introduction of new therapies to the market. Furthermore, disparities in healthcare infrastructure and technology availability can exacerbate inequalities in access to neurorehabilitation. Policy measures and funding initiatives are crucial to addressing these issues and ensuring broader access to advanced treatments. By prioritizing affordability and accessibility, the field can democratize access to neurorehabilitation and improve patient outcomes worldwide.

4. Future Directions

4.1. Enhancing Real-Time Monitoring and Feedback

Enhancing real-time monitoring and feedback in neurorehabilitation involves leveraging advances in wearable technology and AI to provide more sophisticated insights and interventions. By integrating wearable devices with AI algorithms, healthcare providers can obtain real-time data on patient progress and responses during therapy sessions. This enables immediate adjustments in therapy based on patient feedback and physiological signals, optimizing treatment effectiveness [90]. Moreover, AI-driven analytics can identify patterns and trends in patient data, facilitating personalized interventions and predicting potential challenges or complications.

A key question in this context is: How can the integration of real-time monitoring technologies, such as wearable devices and AI, be optimized to track and enhance neuroplasticity during neurorehabilitation, and what specific neuroplastic changes can be observed in response to these interventions? This question explores how real-time monitoring and AI can improve patient outcomes by tracking neuroplastic changes during rehabilitation. Wearable devices and AI continuously monitor brain activity, muscle function, and cognition, offering insights into how the brain adapts to therapy. This data helps clinicians identify neuroplastic changes, like strengthening neural connections or reorganizing brain regions for motor or cognitive tasks. By observing these changes in real-time, clinicians can adjust treatments to meet patients' evolving needs.

AI-driven analytics also detect patterns that indicate when neuroplastic changes are occurring, enabling more precise and personalized interventions. Ultimately, integrating these technologies enhances neurorehabilitation, providing a clearer view of neuroplasticity and leading to better long-term recovery. This approach allows for more adaptive, tailored interventions, improving patient care and quality of life.

4.2. Integration of Neuroplasticity with Other Therapies:

Integrating neuroplasticity-focused interventions with other therapies, such as pharmacological or behavioral treatments, holds significant promise for enhancing overall outcomes in neurorehabilitation. By combining different therapeutic approaches, healthcare providers can simultaneously target multiple aspects of neural recovery and functional improvement. For instance, pharmacological interventions may facilitate neuroplastic changes at the cellular level, while behavioral therapies reinforce positive adaptations and promote functional recovery.

Future research should prioritize rigorous clinical trials to explore the synergies between these interventions, assess their combined efficacy, and identify optimal treatment combinations tailored to various patient populations and conditions. Additionally, investigating the timing and dosage of these therapies could further refine their effectiveness. Through systematic investigation and evidence-based practice, integrating neuroplasticity with complementary therapies can maximize treatment impact and improve outcomes for individuals undergoing neurorehabilitation [11]. Collaborative efforts across disciplines—such as neuroscience, psychology, and pharmacology—will be crucial in driving these advancements and ensuring comprehensive, patient-centered care.

4.3. Developing Non-Invasive Brain Stimulation Techniques:

Future research into emerging brain stimulation techniques offers promising avenues to enhance neurorehabilitation. To fully realize their potential, studies should prioritize refining these non-invasive methods and establishing standardized protocols. This includes optimizing stimulation settings, accurately identifying target brain areas and timing, and developing personalized treatment plans tailored to individual patient needs and specific rehabilitation goals.

A key question must be addressed: "How can non-invasive brain stimulation techniques be optimized to enhance neuroplasticity, and what are the optimal parameters (e.g. timing, intensity, frequency) for inducing lasting neuroplastic changes in the brain?" This question guides the investigation into how various stimulation parameters affect neuroplasticity and which combinations of parameters lead to the most effective rehabilitation outcomes.

Additionally, researchers can tailor interventions to significantly enhance overall treatment outcomes by exploring the integration of brain stimulation with other therapeutic interventions, such as behavioral therapies or pharmacological interventions, and incorporating real-time monitoring with AI-driven feedback. By emphasizing rigorous investigation and validation, these techniques can be effectively incorporated into clinical practice as safe and powerful tools for promoting neural plasticity and achieving optimal results in neurorehabilitation, ultimately improving the quality of care for patients.

4.4. Promoting Longitudinal Clinical Studies

Promoting longitudinal studies is crucial for gaining comprehensive insights into the sustained impacts of neuroplasticity interventions in neurorehabilitation [91] [92]. By conducting long-term studies, researchers can track patients' progress over extended periods, providing a deeper understanding of the lasting effects of interventions on both neuroplasticity and functional outcomes. Moreover, longitudinal studies facilitate the identification of factors that contribute to long-term successes or relapses, such as patient demographics, treatment adherence, and environmental influences.

By elucidating these factors, clinicians can refine treatment protocols, optimize intervention strategies, and develop targeted approaches to enhance long-term neurorehabilitation outcomes. Furthermore, these studies can help uncover how different interventions may interact over time, providing a more nuanced view of patient recovery. Ultimately, promoting longitudinal studies fosters evidence-based practice and enriches our understanding of the dynamics of neuroplasticity within rehabilitation, paving the way for more effective, individualized care for patients.

4.5. Fostering Interdisciplinary Collaboration

Fostering interdisciplinary collaboration is paramount to driving innovation and addressing complex challenges in neuroplasticity research and practice. Collaborating with neuroscientists, engineers, clinicians, and data scientists can influence diverse expertise and perspectives to develop holistic approaches to understanding and harnessing neuroplasticity. Neuroscientists provide insights into the underlying mechanisms of neuroplasticity, while biochemical engineers contribute technological advancements for monitoring and modulating neural activity. In addition, clinicians offer valuable clinical expertise and insights into patient care, while data scientists bring expertise in analyzing complex datasets and extracting meaningful insights. Through these collaborations, researchers can develop innovative solutions, translate research outcomes into clinical practice, and eventually improve outcomes for individuals experiencing neurorehabilitation. This collaborative approach fosters synergy, creativity, and innovation, leading to transformative neuroplasticity research and practice advancements.

4.6. Harnessing Big Data, Machine Learning, and Digital Health Technology

Harnessing big data and ML presents an opportunity to revolutionize neurehabilitation by utilizing vast datasets to gain insights into treatment effectiveness and personalized interventions [93]. The convergence of digital health technology (DHT), big data, and ML represents a transformative paradigm in healthcare, offering unprecedented opportunities for personalized and data-driven approaches to diagnosis, treatment, and patient care. Wearable devices, mobile apps, and telemedicine platforms generate vast amounts of health-related data, including physiological measurements, patient-reported outcomes, and behavioral metrics.

Key questions arise: "How can big data and ML improve the personalization of neurorehabilitation treatments, and what specific data points should be prioritized for analysis?". Additionally, "how can real-time monitoring and predictive analytics contribute to more adaptive and responsive neurorehabilitation treatments?" Big data analytics enables the aggregation, integration, and analysis of this wealth of healthcare data to uncover meaningful patterns, correlations, and insights. Utilizing ML algorithms to large data sets, healthcare providers can obtain actionable knowledge, predict disease outcomes, identify high-risk patient populations, and optimize treatment protocols. For example, ML models can analyze electronic health records to detect patterns indicative of disease progression or adverse events, helping clinicians make more informed decisions and improve patient outcomes.

Furthermore, the integration of ML into DHT enables real-time monitoring, continuous learning, and personalized interventions tailored to individual patient needs. ML algorithms can analyze streaming data from wearable devices to detect anomalies, provide early warnings of health issues, and adapt treatment plans in response to changing patient conditions [94]. By harnessing the combined power of DHT, big data, and ML, healthcare systems can augment efficiency, reduce costs, and deliver more proactive, patient-centered care, ultimately leading to improved neurorehabilitation outcomes.

5. Conclusions

Neuroplasticity is essential in understanding and addressing several neurological disorders such as stroke, TBI, Alzheimer's disease, Parkinson's disease, and even depression. These conditions often lead to cognitive impairments and challenges in daily activities, which stem from abnormalities in neuroplasticity. By comprehending the interplay between neuroplasticity and disease progression, scientists can identify novel therapeutic targets and interventions for neurological disorders, including those with comorbid depression.

Harnessing the principles of neuroplasticity holds immense promise for innovating therapeutic interventions to mitigate the effects of neurological diseases and foster functional recovery. Neurorehabilitation strategies harnessing the brain's plasticity offer pathways to enhance neural repair, restore lost functions, and enhance the quality of life for individuals suffering from neurological conditions. Through tailoring interventions encompassing physical rehabilitation, cognitive training, and sensory stimulation, patients can undergo targeted neuroplastic changes that facilitate recovery and adaptation to neurological impairments, augmenting their overall well-being and functional independence.

Moreover, technological advancements, such as AI using data through DHT, are revolutionizing neurorehabilitation. AI processes vast amounts of patient data, including neuroimaging, genetic, and clinical data, to identify patterns and optimize treatment plans. DHTs, such as wearable devices, mobile apps, and telemedicine platforms, enable remote monitoring, personalized interventions, and improved patient outcomes by integrating with research in neuroplasticity. Interdisciplinary collaboration among neuroscientists, clinicians, engineers, data scientists, and digital health experts fosters innovation and defeats complex disease management and rehabilitation challenges.

The field of neuroplasticity stands poised to advance significantly by addressing the challenges and pursuing future directions. By harnessing personalized medicine approaches, technological innovations, integration of therapies, and interdisciplinary collaboration, neurorehabilitation strategies can become more effective and accessible. This progress can potentially transform the lives of individuals recovering from neurological injuries or conditions, improving their quality of life and functional outcomes. Ultimately, by embracing these opportunities for growth and innovation, the field of neuroplasticity can continue to evolve, driving the development of novel and impactful neurorehabilitation strategies that benefit patients worldwide.

Funding

This research received no external funding

Acknowledgements

This review presents available data honestly and without fabrication, ensuring accurate and appropriate interpretations. I want to thank Dr. Safdar Jawaid, Director of Laboratory Retro Therapy Neuroscience at Splice Therapeutics in Maryland, for his invaluable guidance and review of this manuscript.

Conflicts of Interest

The author declares no conflicts of interest regarding the publication of this paper.

References

[1] Innocenti, G.M. (2022) Defining Neuroplasticity. *Handbook of Clinical Neurology*, **184**, 3-18. https://doi.org/10.1016/b978-0-12-819410-2.00001-1

[2] Puderbaugh, M., and Emmady, P.D. (2023) Neuroplasticity. StatPearls Publishing.

[3] Colavitta, M.F. and Barrantes, F.J. (2023) Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease. *Pharmaceutics*, **15**, Article 2052. https://doi.org/10.3390/pharmaceutics15082052

[4] Paola Caminiti, S., Gallo, S., Menegon, F., Naldi, A., Comi, C. and Tondo, G. (2024) Lifestyle Modulators of Neuroplasticity in Parkinson's Disease: Evidence in Human Neuroimaging Studies. *CNS & Neurological Disorders-Drug Targets*, **23**, 602-613.

https://doi.org/10.2174/1871527322666230616121213

[5] Billot, A. and Kiran, S. (2024) Disentangling Neuroplasticity Mechanisms in Post-Stroke Language Recovery. *Brain and Language*, **251**, Article ID: 105381. https://doi.org/10.1016/j.bandl.2024.105381

[6] Malathi, H., Dhananjoy, L., Tarekar, A., Sharma, K., Mewara, D., *et al.* (2023) Neuroplasticity and Brain Stimulation: Developing Interventions to Promote Recovery from Stroke and Traumatic Brain Injury. *Georgian Medical News*, No. 342, 101-107. http://www.ncbi.nlm.nih.gov/pubmed/37991963

[7] Appelbaum, L.G., Shenasa, M.A., Stolz, L. and Daskalakis, Z. (2022) Synaptic Plasticity and Mental Health: Methods, Challenges and Opportunities. *Neuropsychopharmacology*, **48**, 113-120. https://doi.org/10.1038/s41386-022-01370-w

[8] Cooper, T., Seigler, M.D. and Stahl, S. (2023) Rapid Onset Brain Plasticity at Novel Pharmacologic Targets Hypothetically Drives Innovations for Rapid Onset Antidepressant Actions. *Journal of Psychopharmacology*, **37**, 242-247.

[9] Bandeira, I.D., Lins-Silva, D.H., Barouh, J.L., Faria-Guimarães, D., Dorea-Bandeira, I., Souza, L.S., *et al.* (2021) Neuroplasticity and Non-Invasive Brain Stimulation in the Developing Brain. In: *Progress in Brain Research*, Vol. 268, Elsevier, 57-89. https://doi.org/10.1016/bs.pbr.2021.04.003

[10] Marzola, P., Melzer, T., Pavesi, E., Gil-Mohapel, J. and Brocardo, P.S. (2023) Exploring the Role of Neuroplasticity in Development, Aging, and Neurodegeneration. *Brain Sciences*, **13**, Article 1610. https://doi.org/10.3390/brainsci13121610

[11] Kumar, J., Patel, T., Sugandh, F., Dev, J., Kumar, U., Adeeb, M., *et al.* (2023) Innovative Approaches and Therapies to Enhance Neuroplasticity and Promote Recovery in Patients with Neurological Disorders: A Narrative Review. *Cureus*, **15**, e41914. https://doi.org/10.7759/cureus.41914

[12] Zotey, V., Andhale, A., Shegekar, T. and Juganavar, A. (2023) Adaptive Neuroplasticity in Brain Injury Recovery: Strategies and Insights. *Cureus*, **15**, e45873. https://doi.org/10.7759/cureus.45873

[13] Kirchner, J.H., Euler, L., Fritz, I., Ferreira Castro, A. and Gjorgjieva, J. (2025) Dendritic Growth and Synaptic Organization from Activity-Independent Cues and Local Activity-Dependent Plasticity. *eLife*, **12**, RP87527. https://doi.org/10.7554/elife.87527.3

[14] Riccomagno, M.M. and Kolodkin, A.L. (2015) Sculpting Neural Circuits by Axon and Dendrite Pruning. *Annual Review of Cell and Developmental Biology*, **31**, 779-805. https://doi.org/10.1146/annurev-cellbio-100913-013038

[15] Weerasinghe-Mudiyanselage, P.D.E., Ang, M.J., Kang, S., Kim, J. and Moon, C. (2022) Structural Plasticity of the Hippocampus in Neurodegenerative Diseases. *International Journal of Molecular Sciences*, **23**, Article 3349. https://doi.org/10.3390/ijms23063349

[16] Simons, M., Gibson, E.M. and Nave, K. (2024) Oligodendrocytes: Myelination, Plasticity, and Axonal Support. *Cold Spring Harbor Perspectives in Biology*, **16**, a041359. https://doi.org/10.1101/cshperspect.a041359

[17] Lindsey, H.M., Lazar, M., Mercuri, G., Rath, J.F., Bushnik, T., Flanagan, S., *et al.* (2022) The Effects of Plasticity-Based Cognitive Rehabilitation on Resting-State Functional Connectivity in Chronic Traumatic Brain Injury: A Pilot Study. *NeuroRehabilitation*, **51**, 133-150. https://doi.org/10.3233/nre-210264

[18] Stampanoni Bassi, M., Iezzi, E., Gilio, L., Centonze, D. and Buttari, F. (2019) Synaptic Plasticity Shapes Brain Connectivity: Implications for Network Topology. *International Journal of Molecular Sciences*, **20**, Article 6193.

https://doi.org/10.3390/ijms20246193

[19] Qi, C., Luo, L., Feng, I. and Ma, S. (2022) Molecular Mechanisms of Synaptogenesis. *Frontiers in Synaptic Neuroscience*, **14**, Article 939793. https://doi.org/10.3389/fnsyn.2022.939793

[20] Hogan, M.K., Hamilton, G.F. and Horner, P.J. (2020) Neural Stimulation and Molecular Mechanisms of Plasticity and Regeneration: A Review. *Frontiers in Cellular Neuroscience*, **14**, Article 271. https://doi.org/10.3389/fncel.2020.00271

[21] Azman, K.F. and Zakaria, R. (2022) Recent Advances on the Role of Brain-Derived Neurotrophic Factor (BDNF) in Neurodegenerative Diseases. *International Journal of Molecular Sciences*, **23**, Article 6827. https://doi.org/10.3390/ijms23126827

[22] Ma, H., Khaled, H.G., Wang, X.H., Mandelberg, N.J., Cohen, S.M., He, X.Z., *et al.* (2023) Excitation—Transcription Coupling, Neuronal Gene Expression and Synaptic Plasticity. *Nature Reviews Neuroscience*, **24**, 672-692. https://doi.org/10.1038/s41583-023-00742-5

[23] Pickersgill, J.W., Turco, C.V., Ramdeo, K., Rehsi, R.S., Foglia, S.D. and Nelson, A.J. (2022) The Combined Influences of Exercise, Diet and Sleep on Neuroplasticity. *Frontiers in Psychology*, **13**, Article 831819. https://doi.org/10.3389/fpsyg.2022.831819

[24] Maharjan, R., Diaz Bustamante, L., Ghattas, K.N., Ilyas, S., Al-Refai, R. and Khan, S. (2020) Role of Lifestyle in Neuroplasticity and Neurogenesis in an Aging Brain. *Cureus*, **12**, e10639. https://doi.org/10.7759/cureus.10639

[25] Han, Y., Yuan, M., Guo, Y., Shen, X., Gao, Z. and Bi, X. (2022) The Role of Enriched Environment in Neural Development and Repair. *Frontiers in Cellular Neuroscience*, **16**, Article 890666. https://doi.org/10.3389/fncel.2022.890666

[26] Yuan, S.T., Wu, H.Q., Wu, Y., Xu, H.Z., Yu, J.P., Zhong, Y., *et al.* (2022) Neural Effects of Cognitive Behavioral Therapy in Psychiatric Disorders: A Systematic Review and Activation Likelihood Estimation Meta-Analysis. *Frontiers in Psychology*, **13**, Article 853804. https://doi.org/10.3389/fpsyg.2022.853804

[27] Santiago, J.A. and Potashkin, J.A. (2023) Physical Activity and Lifestyle Modifications in the Treatment of Neurodegenerative Diseases. *Frontiers in Aging Neuroscience*, **15**, Article 1185671. https://doi.org/10.3389/fnagi.2023.1185671

[28] Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B. and Helyes, Z. (2022) Novel Drug Developmental Strategies for Treatment-Resistant Depression. *British Journal of Pharmacology*, **179**, 1146-1186. https://doi.org/10.1111/bph.15753

[29] Cubillos, S., Engmann, O. and Brancato, A. (2022) BDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions. *International Journal of Molecular Sciences*, **23**, Article 14445. https://doi.org/10.3390/ijms232214445

[30] Shamsnia, H.S., Peyrovinasab, A., Amirlou, D., Sirouskabiri, S., Rostamian, F., Basiri, N., *et al.* (2024) BDNF-TrkB Signaling Pathway in Spinal Cord Injury: Insights and Implications. *Molecular Neurobiology*, **62**, 1904-1944. https://doi.org/10.1007/s12035-024-04381-4

[31] Correia, A.S. and Vale, N. (2024) Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances. *International Journal of Translational Medicine*, **4**, 176-196. https://doi.org/10.3390/ijtm4010010

[32] Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G.M., *et al.* (2018) International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-Resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. *Pharmacological Reviews*, **70**, 475-504. https://doi.org/10.1124/pr.117.014977

[33] Rădulescu, I., Drăgoi, A., Trifu, S. and Cristea, M. (2021) Neuroplasticity and Depression: Rewiring the Brain's Networks through Pharmacological Therapy (Review). *Experimental and Therapeutic Medicine*, **22**, Article No. 1131. https://doi.org/10.3892/etm.2021.10565

[34] Pienaar, L., Baijnath, S. and Millen, A.M.E. (2024) Unravelling the Neuroinflammatory Links in Depression: The Potential of a Lipopolysaccharide Preclinical Model. *Discover Medicine*, **1**, Article No. 93. https://doi.org/10.1007/s44337-024-00114-7

[35] Shi, X., Du, Y., Chen, L., Li, X.-S., Yao, C.-Q. and Cheng, Y. (2022) Effects of Brain-Derived Neurotrophic Factor (BDNF) on the Schizophrenia Model of Animals. *Journal of Psychiatric Research*, **156**, 538-546. https://doi.org/10.1016/j.jpsychires.2022.10.022

[36] Matveychuk, D., MacKenzie, E.M., Kumpula, D., Song, M., Holt, A., Kar, S., *et al.* (2021) Overview of the Neuroprotective Effects of the Mao-Inhibiting Antidepressant Phenelzine. *Cellular and Molecular Neurobiology*, **42**, 225-242. https://doi.org/10.1007/s10571-021-01078-3

[37] Edinoff, A.N., Swinford, C.R., Odisho, A.S., Burroughs, C.R., Stark, C.W., Raslan, W.A., *et al.* (2022) Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. *Health Psychology Research*, **10**, 1-13. https://doi.org/10.52965/001c.39576

[38] Fitzgerald, P.J., Hale, P.J., Ghimire, A. and Watson, B.O. (2020) The Cholinesterase Inhibitor Donepezil Has Antidepressant-Like Properties in the Mouse Forced Swim Test. *Translational Psychiatry*, **10**, Article No. 255. https://doi.org/10.1038/s41398-020-00928-w

[39] Zanos, P., Brown, K.A., Georgiou, P., Yuan, P., Zarate, C.A., Thompson, S.M., *et al.* (2023) NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine. *The Journal of Neuroscience*, **43**, 1038-1050. https://doi.org/10.1523/jneurosci.1316-22.2022

[40] Nicoletti, V.G., Pajer, K., Calcagno, D., Pajenda, G. and Nógrádi, A. (2022) The Role of Metals in the Neuroregenerative Action of BDNF, GDNF, NGF and Other Neurotrophic Factors. *Biomolecules*, **12**, Article 1015. https://doi.org/10.3390/biom12081015

[41] Riva, N., Domi, T., Pozzi, L., Lunetta, C., Schito, P., Spinelli, E.G., *et al.* (2024) Update on Recent Advances in Amyotrophic Lateral Sclerosis. *Journal of Neurology*, **271**, 4693-4723. https://doi.org/10.1007/s00415-024-12435-9

[42] Kohn, D.B., Chen, Y.Y. and Spencer, M.J. (2023) Successes and Challenges in Clinical Gene Therapy. *Gene Therapy*, **30**, 738-746. https://doi.org/10.1038/s41434-023-00390-5

[43] Hu, J.Q. and Wang, X.C. (2022) Alzheimer's Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy—Bridging the Missing Link. *Frontiers in Cellular Neuroscience*, **15**, Article 811852. https://doi.org/10.3389/fncel.2021.811852

[44] Li, K., Li, X.Y., Shi, G.Y., Lei, X.P., Huang, Y.Y., Bai, L., *et al.* (2021) Effectiveness and Mechanisms of Adipose-Derived Stem Cell Therapy in Animal Models of Parkinson's Disease: A Systematic Review and Meta-Analysis. *Translational Neurodegeneration*, **10**, Article No. 14. https://doi.org/10.1186/s40035-021-00238-1

[45] Wang, F., Sun, Z.G., Peng, D.Y., Gianchandani, S., Le, W., Boltze, J., *et al.* (2023) Cell-Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis. *Journal of Translational Medicine*, **21**, Article No. 601. https://doi.org/10.1186/s12967-023-04484-x

[46] Tang, X.G., Deng, P., Li, L., He, Y.Q., Wang, J.C., Hao, D.G., *et al.* (2024) Advances in Genetically Modified Neural Stem Cell Therapy for Central Nervous System Injury and Neurological Diseases. *Stem Cell Research & Therapy*, **15**, Article No. 482.

https://doi.org/10.1186/s13287-024-04089-1

[47] Cao, Z.M., Kong, F.S., Ding, J.Q., Chen, C.X., He, F.M. and Deng, W.B. (2024) Promoting Alzheimer's Disease Research and Therapy with Stem Cell Technology. *Stem Cell Research & Therapy*, **15**, Article No. 136. https://doi.org/10.1186/s13287-024-03737-w

[48] Mariottini, A., De Matteis, E., Cencioni, M.T. and Muraro, P.A. (2023) Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances. *Current Neurology and Neuroscience Reports*, **23**, 507-520. https://doi.org/10.1007/s11910-023-01290-2

[49] Shah, S., Mansour, H.M. and Lucke-Wold, B. (2025) Advances in Stem Cell Therapy for Huntington's Disease: A Comprehensive Literature Review. *Cells*, **14**, Article 42. https://doi.org/10.3390/cells14010042

[50] Amado, D.A. and Davidson, B.L. (2021) Gene Therapy for ALS: A Review. *Molecular Therapy*, **29**, 3345-3358. https://doi.org/10.1016/j.ymthe.2021.04.008

[51] Inamdar, A.C. and Inamdar, A.A. (2013) Mesenchymal Stem Cell Therapy in Lung Disorders: Pathogenesis of Lung Diseases and Mechanism of Action of Mesenchymal Stem Cell. *Experimental Lung Research*, **39**, 315-327. https://doi.org/10.3109/01902148.2013.816803

[52] Weston, N.M. and Sun, D. (2018) The Potential of Stem Cells in Treatment of Traumatic Brain Injury. *Current Neurology and Neuroscience Reports*, **18**, Article No. 1. https://doi.org/10.1007/s11910-018-0812-z

[53] Nouri Nojadeh, J., Bildiren Eryilmaz, N.S., and Erguder, B.I. (2023) CRISPR/Cas9 Genome Editing for Neurodegenerative Diseases. *EXCLI Journal*, **22**, 567-582.

[54] Aslesh, T. and Yokota, T. (2022) Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy. *Cells*, **11**, Article 417. https://doi.org/10.3390/cells11030417

[55] Ng, J., Barral, S., Waddington, S.N. and Kurian, M.A. (2023) Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases. *Movement Disorders*, **38**, 924-936. https://doi.org/10.1002/mds.29416

[56] Langin, L., Johnson, T.B., Kovács, A.D., Pearce, D.A. and Weimer, J.M. (2020) A Tailored *Cln3*^{Q352X} Mouse Model for Testing Therapeutic Interventions in CLN3 Batten Disease. *Scientific Reports*, **10**, Article No. 10591. https://doi.org/10.1038/s41598-020-67478-5

[57] Lenze, E.J., Nicol, G.E., Barbour, D.L., Kannampallil, T., Wong, A.W.K., Piccirillo, J., *et al.* (2021) Precision Clinical Trials: A Framework for Getting to Precision Medicine for Neurobehavioural Disorders. *Journal of Psychiatry and Neuroscience*, **46**, E97-E110. https://doi.org/10.1503/jpn.200042

[58] Yadav, V.K., Dhanasekaran, S., Choudhary, N., Nathiya, D., Thakur, V., Gupta, R., *et al.* (2025) Recent Advances in Nanotechnology for Parkinson's Disease: Diagnosis, Treatment, and Future Perspectives. *Frontiers in Medicine*, **12**, Article 1535682. https://doi.org/10.3389/fmed.2025.1535682

[59] Amano, A., Sanjo, N., Araki, W., Anraku, Y., Nakakido, M., Matsubara, E., *et al.* (2023) Peripheral Administration of Nanomicelle-Encapsulated Anti-Aβ Oligomer Fragment Antibody Reduces Various Toxic Aβ Species in the Brain. *Journal of Nanobiotechnology*, **21**, Article No. 36. https://doi.org/10.1186/s12951-023-01772-y

[60] Asefy, Z., Hoseinnejhad, S. and Ceferov, Z. (2021) Nanoparticles Approaches in Neurodegenerative Diseases Diagnosis and Treatment. *Neurological Sciences*, **42**, 2653-2660. https://doi.org/10.1007/s10072-021-05234-x

[61] Kumar, A., Chaudhary, R.K., Singh, R., Singh, S.P., Wang, S.-Y., Hoe, Z.-Y., *et al.* (2020) Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases. *Frontiers in Neuroscience*, **14**, Article 305. https://doi.org/10.3389/fnins.2020.00305

[62] Ajoolabady, A., Aslkhodapasandhokmabad, H., Henninger, N., Demillard, L.J., Nikanfar, M., Nourazarian, A., *et al.* (2021) Targeting Autophagy in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Therapeutics. *Clinical and Experimental Pharmacology and Physiology*, **48**, 943-953. https://doi.org/10.1111/1440-1681.13500

[63] Neumann, N.R., Thompson, D.C. and Vasiliou, V. (2021) AMPK Activators for the Prevention and Treatment of Neurodegenerative Diseases. *Expert Opinion on Drug Metabolism & Toxicology*, **17**, 1199-1210. https://doi.org/10.1080/17425255.2021.1991308

[64] Querfurth, H. and Lee, H. (2021) Mammalian/Mechanistic Target of Rapamycin (mTOR) Complexes in Neurodegeneration. *Molecular Neurodegeneration*, **16**, Article No. 44. https://doi.org/10.1186/s13024-021-00428-5

[65] Liénard, C., Pintart, A. and Bomont, P. (2024) Neuronal Autophagy: Regulations and Implications in Health and Disease. *Cells*, **13**, Article 103. https://doi.org/10.3390/cells13010103

[66] Calder, A.E. and Hasler, G. (2022) Towards an Understanding of Psychedelic-Induced Neuroplasticity. *Neuropsychopharmacology*, **48**, 104-112. https://doi.org/10.1038/s41386-022-01389-z

[67] Bhunia, S., Kolishetti, N., Arias, A.Y., Vashist, A. and Nair, M. (2022) Cannabidiol for Neurodegenerative Disorders: A Comprehensive Review. *Frontiers in Pharmacology*, **13**, Article 989717. https://doi.org/10.3389/fphar.2022.989717

[68] Marzi, S.J., Schilder, B.M., Nott, A., Frigerio, C.S., Willaime-Morawek, S., Bucholc, M., *et al.* (2023) Artificial Intelligence for Neurodegenerative Experimental Models. *Alzheimer's & Dementia*, **19**, 5970-5987. https://doi.org/10.1002/alz.13479

[69] Coetzer, R. and da Silva Ramos, S. (2022) A Neurobehavioral Therapy Approach to the Rehabilitation and Support of Persons with Brain Injury: Practice-Based Evidence from a UK Charitable Rehabilitation Provider. *Frontiers in Rehabilitation Sciences*, **3**, Article 902702. https://doi.org/10.3389/fresc.2022.902702

[70] Jang, J., Oh, S., Kim, G., Lee, N., Song, H., Park, J., *et al.* (2023) Analysis of the Effectiveness of Cognitive Rehabilitation for Patients with Chronic Mental Illness: A Meta-analysis. *World Journal of Clinical Cases*, **11**, 7822-7832. https://doi.org/10.12998/wjcc.v11.i32.7822

[71] Forman, C.R., Nielsen, J.B. and Lorentzen, J. (2021) Neuroplasticity at Home: Improving Home-Based Motor Learning through Technological Solutions. a Review. *Frontiers in Rehabilitation Sciences*, **2**, Article 789165. https://doi.org/10.3389/fresc.2021.789165

[72] Hasan, I., Reza, M.S., Haider, S.S., Haque, M.E. and Emran, T.B. (2023) Disease-Specific Recommendation for Rehabilitation: Perspective from Neurodegenerative Diseases. *Annals of Medicine & Surgery*, **85**, 64-66. https://doi.org/10.1097/ms9.0000000000000157

[73] Yuan, T.-F., Li, W.-G., Zhang, C.C., Wei, H.J., Sun, S.Y., Xu, N.-J., *et al.* (2020) Targeting Neuroplasticity in Patients with Neurodegenerative Diseases Using Brain Stimulation Techniques. *Translational Neurodegeneration*, **9**, Article No. 44. https://doi.org/10.1186/s40035-020-00224-z

[74] Cortright, M.K., Bluhm, R., Achtyes, E.D., McCright, A.M. and Cabrera, L.Y. (2024) Perceived Barriers to Using Neurostimulation. *The Journal of ECT*, **40**, 111-117.

https://doi.org/10.1097/yct.0000000000000990

[75] Fitzsimmons, S.M.D.D., Oostra, E., Postma, T.S., van der Werf, Y.D. and van den Heuvel, O.A. (2024) Repetitive Transcranial Magnetic Stimulation-Induced Neuroplasticity and the Treatment of Psychiatric Disorders: State of the Evidence and Future Opportunities. *Biological Psychiatry*, **95**, 592-600. https://doi.org/10.1016/j.biopsych.2023.11.016

[76] Cammisuli, D.M., Cignoni, F., Ceravolo, R., Bonuccelli, U. and Castelnuovo, G. (2022) Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients with Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. *Frontiers in Neurology*, **12**, Article 798191. https://doi.org/10.3389/fneur.2021.798191

[77] Barbati, S.A., Podda, M.V. and Grassi, C. (2022) Tuning Brain Networks: The Emerging Role of Transcranial Direct Current Stimulation on Structural Plasticity. *Frontiers in Cellular Neuroscience*, **16**, Article 945777. https://doi.org/10.3389/fncel.2022.945777

[78] Brambilla, C., Pirovano, I., Mira, R.M., Rizzo, G., Scano, A. and Mastropietro, A. (2021) Combined Use of EMG and EEG Techniques for Neuromotor Assessment in Rehabilitative Applications: A Systematic Review. *Sensors*, **21**, Article 7014. https://doi.org/10.3390/s21217014

[79] Vilou, I., Varka, A., Parisis, D., Afrantou, T. and Ioannidis, P. (2023) EEG-Neurofeedback as a Potential Therapeutic Approach for Cognitive Deficits in Patients with Dementia, Multiple Sclerosis, Stroke and Traumatic Brain Injury. *Life*, **13**, Article 365. https://doi.org/10.3390/life13020365

[80] Sandoval-Pistorius, S.S., Hacker, M.L., Waters, A.C., Wang, J., Provenza, N.R., de Hemptinne, C., *et al.* (2023) Advances in Deep Brain Stimulation: From Mechanisms to Applications. *The Journal of Neuroscience*, **43**, 7575-7586. https://doi.org/10.1523/jneurosci.1427-23.2023

[81] Roalf, D.R., Figee, M. and Oathes, D.J. (2024) Elevating the Field for Applying Neuroimaging to Individual Patients in Psychiatry. *Translational Psychiatry*, **14**, Article No. 87. https://doi.org/10.1038/s41398-024-02781-7

[82] Tae, W., Ham, B., Pyun, S., Kang, S. and Kim, B. (2018) Current Clinical Applications of Diffusion-Tensor Imaging in Neurological Disorders. *Journal of Clinical Neurology*, **14**, 129-140. https://doi.org/10.3988/jcn.2018.14.2.129

[83] Micoulaud-Franchi, J.A., Jeunet, C., Pelissolo, A. and Ros, T. (2021) EEG Neurofeedback for Anxiety Disorders and Post-Traumatic Stress Disorders: A Blueprint for a Promising Brain-Based Therapy. *Current Psychiatry Reports*, **23**, Article No. 84. https://doi.org/10.1007/s11920-021-01299-9

[84] Farina, D. and Mrachacz-Kersting, N. (2021) Brain-Computer Interfaces and Plasticity of the Human Nervous System. *The Journal of Physiology*, **599**, 2349-2350. https://doi.org/10.1113/jp279845

[85] Broncel, A., Bocian, R., Kłos-Wojtczak, P., Kulbat-Warycha, K. and Konopacki, J. (2020) Vagal Nerve Stimulation as a Promising Tool in the Improvement of Cognitive Disorders. *Brain Research Bulletin*, **155**, 37-47. https://doi.org/10.1016/j.brainresbull.2019.11.011

[86] Baek, H., Pahk, K.J. and Kim, H. (2017) A Review of Low-Intensity Focused Ultrasound for Neuromodulation. *Biomedical Engineering Letters*, **7**, 135-142. https://doi.org/10.1007/s13534-016-0007-y

[87] Lee, K., Park, T.Y., Lee, W. and Kim, H. (2024) A Review of Functional Neuromodulation in Humans Using Low-Intensity Transcranial Focused Ultrasound. *Biomedical*

Engineering Letters, **14**, 407-438. https://doi.org/10.1007/s13534-024-00369-0

[88] Feinsinger, A., Pouratian, N., Ebadi, H., Adolphs, R., Andersen, R., Beauchamp, M.S., *et al.* (2022) Ethical Commitments, Principles, and Practices Guiding Intracranial Neuroscientific Research in Humans. *Neuron*, **110**, 188-194. https://doi.org/10.1016/j.neuron.2021.11.011

[89] Cortes, D. and Pera, M.F. (2021) The Genetic Basis of Inter-Individual Variation in Recovery from Traumatic Brain Injury. *NPJ Regenerative Medicine*, **6**, Article No. 5. https://doi.org/10.1038/s41536-020-00114-y

[90] Surianarayanan, C., Lawrence, J.J., Chelliah, P.R., Prakash, E. and Hewage, C. (2023) Convergence of Artificial Intelligence and Neuroscience towards the Diagnosis of Neurological Disorders—A Scoping Review. *Sensors*, **23**, Article 3062. https://doi.org/10.3390/s23063062

[91] Sauzet, O., Kleine, M., Menzel-Begemann, A. and Exner, A. (2015) Longitudinal Randomised Controlled Trials in Rehabilitation Post-Stroke: A Systematic Review on the Quality of Reporting and Use of Baseline Outcome Values. *BMC Neurology*, **15**, Article No. 99. https://doi.org/10.1186/s12883-015-0344-y

[92] Siegert, R.J., Jackson, D.M., Playford, E.D., Fleminger, S. and Turner-Stokes, L. (2014) A Longitudinal, Multicentre, Cohort Study of Community Rehabilitation Service Delivery in Long-Term Neurological Conditions. *BMJ Open*, **4**, e004231. https://doi.org/10.1136/bmjopen-2013-004231

[93] Raju, B., Jumah, F., Ashraf, O., Narayan, V., Gupta, G., Sun, H., *et al.* (2021) Big Data, Machine Learning, and Artificial Intelligence: A Field Guide for Neurosurgeons. *Journal of Neurosurgery*, **135**, 373-383. https://doi.org/10.3171/2020.5.jns201288

[94] Creagh, A.P., Hamy, V., Yuan, H., Mertes, G., Tomlinson, R., Chen, W., *et al.* (2024) Digital Health Technologies and Machine Learning Augment Patient Reported Outcomes to Remotely Characterise Rheumatoid Arthritis. *NPJ Digital Medicine*, **7**, Article No. 33. https://doi.org/10.1038/s41746-024-01013-y